SCHEMBL4937229

SCHEMBL4937229

CCN1CCC[C@H]1C(=O)OCCN1C(=O)CCC(N2C(=O)c3ccccc3C2=O)C1=O

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD17B10 Q99714 2/20 0.37
PKM P14618 1/20 0.37
LTA4H P09960 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CHRM3 P20309 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4937222 1.00 MAP1LC3B (0.40) MAP1LC3BMEN1KMT2AL3MBTL1HSD17B10
SCHEMBL19889406 0.91 DDB1 (0.42) MAP1LC3BMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL4938313 0.91 TMEM97 (0.41) MAP1LC3BMEN1KMT2AALDH1A1KDM4E
SCHEMBL4938307 0.91 TMEM97 (0.41) MAP1LC3BMEN1KMT2AALDH1A1KDM4E
SCHEMBL13167683 0.91 MEN1 (0.41) MAP1LC3BMEN1KMT2AL3MBTL1HSD17B10
SCHEMBL2916083 0.91 MEN1 (0.41) MAP1LC3BMEN1KMT2AL3MBTL1HSD17B10
SCHEMBL4939014 0.90 DDB1 (0.41) MAP1LC3BMEN1KMT2AALDH1A1KDM4E
SCHEMBL4939022 0.90 DDB1 (0.41) MAP1LC3BMEN1KMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL3580660 0.90 MEN1 (0.40) MAP1LC3BMEN1KMT2AL3MBTL1HSD17B10
SCHEMBL4938823 0.90 DDB1 (0.39) MAP1LC3BMEN1KMT2AHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1867649-B1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-12-12 EP claimed
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-09-10 US disclosed
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-08-15 US disclosed
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-01-01 US disclosed
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2018-02-22 US disclosed
US-9669015-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-06-06 US disclosed
US-20150272940-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2015-10-01 US disclosed
US-9085563-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-07-21 US disclosed
US-20140179737-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-06-26 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
EP-1867649-B1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-12-12 EP disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed
EP-1867649-A1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNFRSF9, TNFRSF1A, NGFR MAP1LC3B 4572/4885MEN1 3574/4885KMT2A 4843/4885
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4651/4885MEN1 3671/4885KMT2A 4780/4885
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNFRSF1A, TNFRSF9, NGFR MAP1LC3B 4580/4885MEN1 3529/4885KMT2A 4841/4885
US-20150272940-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4651/4885MEN1 3671/4885KMT2A 4780/4885
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4631/4885MEN1 3771/4885KMT2A 4804/4885
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4651/4885MEN1 3671/4885KMT2A 4780/4885
US-20140179737-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4651/4885MEN1 3671/4885KMT2A 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.